Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

• Conditions: Metastatic Breast Cancer

• Registration Number: NCT03763604
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-12-03
• Study First Submitted QC: 2018-12-03
• Study First Posted: 2018-12-04
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-11
• Last Update Posted: 2024-12-16

Recruitment & Eligibility

• Status: APPROVED_FOR_MARKETING
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.

Exclusion Criteria

Not provided

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (154)

Liverpool Hospital; 🇦🇺 Liverpool, New South Wales, Australia

North West Cancer Centre; 🇦🇺 North Tamworth, New South Wales, Australia

St Vincent's Hospital Sydney; 🇦🇺 Sydney, New South Wales, Australia

Mater Hospital Sydney; 🇦🇺 Sydney, New South Wales, Australia

Westmead Hospital; 🇦🇺 Westmead, New South Wales, Australia

Wollongong Hospital; 🇦🇺 Wollongong, New South Wales, Australia

Royal Adelaide Hospital; 🇦🇺 Adelaide, South Australia, Australia

Adelaide Oncology and Haematology, Calvary Central Districts Hospital; 🇦🇺 Elizabeth Vale, South Australia, Australia

Icon Cancer Centre - Hobart; 🇦🇺 Hobart, Tasmania, Australia

Royal Hobart Hospital; 🇦🇺 Hobart, Tasmania, Australia

Scroll for more (144 remaining)